Good news in the fight against breast cancer. A study published in "The Lancet Oncology" finds that when two cancer drugs join forces they significantly reduce tumor size.
Women with "Her-2 Positive" breast cancer were treated with a combination of both drugs. After six weeks, those patients had tumors 22 percent smaller than women taking either drug alone.
Herceptin is already approved for breast cancer. Tykerb has only been used for treatment of advanced cancer. This is the first time they have been tested together.
Copyright 2012 Scripps Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
A crash involving a suspected drunk driver strands a Washington, DC man in a Baltimore-area rehabilitation hospital. And all he wants is to go home for the holidays.
The slow rollout of a new federal health insurance marketplace may be deepening differences in health coverage among Americans, with residents in some states gaining insurance at a far greater rate than others.
New research says tens of thousands of women each year might be able to skip at least some of the grueling treatments for breast cancer without greatly harming their odds of survival.